Introduction: Digital health technologies delivering dietary and lifestyle advice(1,2) may offer a contemporary approach to menopause symptom mitigation in a large population base(3). This study aimed to evaluate alterations in both diet quality and menopause symptom burden following the implementation of an app-based, personalised dietary intervention in peri- and postmenopausal participants.
Methods: Baseline and follow-up data (mean follow-up time, 207±72 days) on diet, menopause symptom number (from 20 vasomotor, sexual, psychological and somatic symptoms), symptom severity (0-not at all, 1-a little, 3-quite a bit and 5-extremely) and other characteristics of 4,287 UK based participants of the ZOE PREDICT 3 study (1,000 perimenopausal and 3,287 postmenopausal) were analysed (NCT04735835). Dietary assessment was performed through an app-based food frequency questionnaire (PREDICT-FFQ)(2) and diet quality assessed using the Healthy Eating Index-2020 (HEI, score 0-100)(4). A novel Menopause Symptom Tracker Score (MSTS 0-100, Copyright © 2024 Zoe Limited) was used to capture symptom number and severity.
Results: There was a modest increase in diet quality after the intervention in both peri- and postmenopausal participants; mean HEI from 76.4±8.4 to 79.7±6.8 (P<0.001) and from 78.7±7.8 to 81.1±6.4 (P<0.001), respectively. Baseline MSTS was higher in peri- versus postmenopausal participants 28.9±15.1  vs. 18.1±15.0 (P<0.001). However, both groups showed a significant decrease in mean MSTS after the intervention compared to baseline; mean change (95%CI) in perimenopausal was -8.7 (-9.5, -7.9; 30.1% reduction) and in postmenopausal was -6.6 (-6.9, -6.2; 36.5% reduction) (P for both <0.001). The % reduction in the overall MSTS was greater in postmenopausal compared to perimenopausal (P<0.001). Reductions in domain-specific MSTS for peri- and postmenopausal groups respectively, were as follows: vasomotor -0.56 (-0.71, -0.40; 24.9% reduction) and -0.47 (-0.54, -0.41; 31.8% reduction), sexual -0.72 (-0.87, -0.57; 18.6%) and -1.08 (-1.16, -0.99; 28.7%), psychological -2.3 (-2.5, -2.0; 35.0%) and -1.2 (-1.3, -1.1; 44.2%), somatic -5.1 (-5.6, -4.7; 31.5%) and -3.8 (-4.0, -3.6; 37.5%) (P for all <0.001). The reduction in the psychological and somatic domain-specific MSTS was greater in peri- compared to postmenopausal group (P for both <0.001).
Conclusion: This study supports the potential of personalised app-based dietary interventions in the mitigation of menopausal symptoms during menopause transition and its potential to affect the health and quality of life of millions. Further studies should investigate their efficacy in a randomised, controlled dietary intervention setting.

**Introduction:** Digital health technologies delivering dietary and lifestyle advice^(1,2)^ may offer a contemporary approach to menopause symptom mitigation in a large population base^(3)^. This study aimed to evaluate alterations in both diet quality and menopause symptom burden following the implementation of an app-based, personalised dietary intervention in peri- and postmenopausal participants.
**Methods:** Baseline and follow-up data (mean follow-up time, 207±72 days) on diet, menopause symptom number (from 20 vasomotor, sexual, psychological and somatic symptoms), symptom severity (0-not at all, 1-a little, 3-quite a bit and 5-extremely) and other characteristics of 4,287 UK based participants of the ZOE PREDICT 3 study (1,000 perimenopausal and 3,287 postmenopausal) were analysed (NCT04735835). Dietary assessment was performed through an app-based food frequency questionnaire (PREDICT-FFQ)^(2)^ and diet quality assessed using the Healthy Eating Index-2020 (HEI, score 0-100)^(4)^. A novel Menopause Symptom Tracker Score (MSTS 0-100, Copyright © 2024 Zoe Limited) was used to capture symptom number and severity.
**Results:** There was a modest increase in diet quality after the intervention in both peri- and postmenopausal participants; mean HEI from 76.4±8.4 to 79.7±6.8 (_P_<0.001) and from 78.7±7.8 to 81.1±6.4 (_P_<0.001), respectively. Baseline MSTS was higher in peri- versus postmenopausal participants 28.9±15.1  vs. 18.1±15.0 (_P_<0.001). However, both groups showed a significant decrease in mean MSTS after the intervention compared to baseline; mean change (95%CI) in perimenopausal was -8.7 (-9.5, -7.9; 30.1% reduction) and in postmenopausal was -6.6 (-6.9, -6.2; 36.5% reduction) (_P_ for both <0.001). The % reduction in the overall MSTS was greater in postmenopausal compared to perimenopausal (_P_<0.001). Reductions in domain-specific MSTS for peri- and postmenopausal groups respectively, were as follows: vasomotor -0.56 (-0.71, -0.40; 24.9% reduction) and -0.47 (-0.54, -0.41; 31.8% reduction), sexual -0.72 (-0.87, -0.57; 18.6%) and -1.08 (-1.16, -0.99; 28.7%), psychological -2.3 (-2.5, -2.0; 35.0%) and -1.2 (-1.3, -1.1; 44.2%), somatic -5.1 (-5.6, -4.7; 31.5%) and -3.8 (-4.0, -3.6; 37.5%) (_P_ for all <0.001). The reduction in the psychological and somatic domain-specific MSTS was greater in peri- compared to postmenopausal group (_P_ for both <0.001).
**Conclusion:** This study supports the potential of personalised app-based dietary interventions in the mitigation of menopausal symptoms during menopause transition and its potential to affect the health and quality of life of millions. Further studies should investigate their efficacy in a randomised, controlled dietary intervention setting.

OC112 - Reduction in menopause symptom severity following a personalised app-based dietary intervention program: a pre-post longitudinal analysis of the ZOE PREDICT 3 study

Unique to the new Congress (previously the Summer Conference) is that you will have greater opportunity to engage with more nutrition science than ever before. In 2024 the core programme will be delivered by the Irish Section of The Nutrition Society, supported by the Science Committee. The theme of these symposia will be ‘new data – focused approaches and challenges’. Outside of the core programme you will have the chance to hear the latest research from the Society’s partner organisations, universities, the private sector and more, on a diverse range of research.